Baclofen Tapering Protocol
For sustained-release oral baclofen 20 mg, taper by reducing the dose by 5 mg every 3-7 days, extending the taper over 2-4 weeks minimum to prevent potentially life-threatening withdrawal symptoms including seizures, hallucinations, and respiratory failure.
Critical Safety Warning
Never discontinue baclofen abruptly. Abrupt withdrawal can cause severe, life-threatening complications including hyperpyrexia, seizures, delirium, hallucinations, profound muscle rigidity, and respiratory failure requiring mechanical ventilation 1, 2, 3. Withdrawal symptoms typically emerge within 1-4 days of cessation and can mimic meningoencephalitis or neuroleptic malignant syndrome 2, 3.
Recommended Tapering Schedule
Standard Taper (2-4 weeks)
- Week 1: Reduce from 20 mg to 15 mg daily (5 mg reduction)
- Week 2: Reduce from 15 mg to 10 mg daily (5 mg reduction)
- Week 3: Reduce from 10 mg to 5 mg daily (5 mg reduction)
- Week 4: Discontinue after 3-7 days at 5 mg
This approach is based on FDA labeling guidance recommending slow withdrawal 1 and clinical evidence showing that gradual tapers over 2-4 weeks minimize withdrawal risk 4.
Extended Taper (for patients on baclofen >1 year or higher doses)
For patients who have been on baclofen long-term or who develop withdrawal symptoms during tapering:
- Slow to 5 mg reductions every 7-14 days rather than every 3-7 days
- Total taper duration: 4-8 weeks or longer
- Consider even smaller decrements (2.5 mg) if withdrawal symptoms emerge
Monitoring Requirements
Weekly follow-up is mandatory during tapering to assess for:
- Neuropsychiatric symptoms: Anxiety, agitation, confusion, hallucinations, delirium (present in up to 20.6% of withdrawal cases) 2
- Autonomic instability: Hyperpyrexia (>103°F), tachycardia, hypertension, diaphoresis
- Neuromuscular symptoms: Tremors, muscle rigidity, spasticity rebound, seizures (36% of severe cases) 2
- Respiratory status: Tachypnea, respiratory distress
Management of Withdrawal Symptoms
If withdrawal symptoms develop during taper:
- Immediately reinstate the previous baclofen dose - this consistently resolves symptoms 2, 3
- Stabilize for 1-2 weeks at the higher dose
- Resume taper at a slower rate (reduce by 2.5 mg every 7-14 days)
- Consider adjunctive benzodiazepines for severe agitation or seizure risk
- Escalate to ICU monitoring if severe autonomic instability or respiratory compromise develops
High-Risk Situations
Do not attempt outpatient taper if:
- Patient has history of seizures
- Previous severe withdrawal symptoms
- Concurrent alcohol or benzodiazepine use
- Doses ≥300 mg/day (associated with 54.5% intubation rate in toxicity cases) 2
These patients require inpatient monitoring during taper.
Key Clinical Pitfalls
- Mistaking withdrawal for disease relapse: Spasticity rebound during taper may represent withdrawal rather than underlying condition worsening. If uncertain, reinstate previous dose and reassess 2
- Underestimating withdrawal severity: Oral baclofen withdrawal can be as severe as intrathecal withdrawal, with documented cases requiring mechanical ventilation 3
- Inadequate patient education: Patients must understand they cannot abruptly stop baclofen and must contact you immediately if withdrawal symptoms develop
- Failure to account for sustained-release formulation: SR formulations may have delayed withdrawal onset; monitor for 5-7 days after each dose reduction
Patient-Centered Approach
While the evidence base for baclofen tapering is limited to case reports and retrospective studies 2, 3, the consistent finding across all reports is that gradual dose reduction prevents severe withdrawal. The 2-4 week taper recommendation from geriatric guidelines 4 provides a practical starting framework, but you must be prepared to extend the taper significantly if withdrawal symptoms emerge, potentially over several months as demonstrated in similar GABA-ergic medications 5.
Document your tapering plan explicitly and ensure the patient has emergency contact information if withdrawal symptoms develop between visits.